ArticleFolia microbiologica2026
Microbial degradation of acetaminophen, a pharmaceutical compound, using the ascomycete fungus Trichoderma asperellum.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tropical fungus Trichoderma asperellum was identified as a novel acetaminophen degrader, achieving 88.8% removal of 1 g/L acetaminophen in liquid culture under optimal conditions (pH 4.7, 0.55% w/v salinity, 9.7 g/L glucose, and 4.5 g/L peptone). A unique enzyme pattern, predominantly dioxygenase (146 U/mL on day 7), exhibited a degradation mechanism distinct from the ligninolytic enzyme system traditionally associated with fungal biodegradation. The GC-MS analysis has identified some intermediates, including p-aminophenol, 1,3-dihydroxybenzene, phenol, and butenoic acid. At the same time, some of the metabolites have not been reported previously in fungal degradation of acetaminophen. The distinct pattern of enzyme response and the identification of novel intermediates indicate that T. asperellum follows a distinct oxidative hydrolytic route, highlighting its potential as a new fungal candidate for the bioremediation of pharmaceuticals.
Indexed as
Identifiers
41801550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.